Loading…
for educational and safety purposes
4-HO-DiPT and 4-AcO-DiPT both come up in the same conversations; they overlap on Serotonin. 4-HO-DiPT: 4-HO-DiPT (4-hydroxy-N,N-diisopropyltryptamine) is a synthetic tryptamine and the diisopropyl homolog of psilocin. 4-AcO-DiPT: 4-AcO-DiPT (4-acetoxy-N,N-diisopropyltryptamine) is a synthetic tryptamine, the acetate ester of 4-HO-DiPT and a member of the diisopropyltryptamine family.
4-HO-DiPT (4-hydroxy-N,N-diisopropyltryptamine) is a synthetic tryptamine and the diisopropyl homolog of psilocin. It acts as an agonist at the 5-HT2A serotonin receptor, and preclinical target profiling indicates broader activity across serotonin receptor subtypes typical of the tryptamine class; in rats it fully substitutes for the discriminative stimulus of the psychedelic DOM. Its distinguishing feature is an unusually rapid onset and notably short duration of action, a property that motivated development of RE104, a glutarate ester prodrug of 4-HO-DiPT that has entered phase 1 human trials as a shorter-duration alternative to psilocybin for depressive disorders. Human pharmacokinetic work shows plasma 4-HO-DiPT appearing within about an hour and correlating with mystical-type and drug-effect measures, and its metabolism proceeds mainly through glucuronidation, sulfation, and N-dealkylation.
4-AcO-DiPT (4-acetoxy-N,N-diisopropyltryptamine) is a synthetic tryptamine, the acetate ester of 4-HO-DiPT and a member of the diisopropyltryptamine family. It is thought to act as a prodrug that undergoes ester hydrolysis to the active 4-HO-DiPT, a 5-HT2A serotonin receptor agonist; human hepatocyte studies confirm rapid deacetylation followed by glucuronidation and sulfation. The diisopropyl tryptamines are pharmacologically distinctive for producing marked auditory distortion, and controlled work on the parent N,N-diisopropyltryptamine describes a frequency-selective downward shift in perceived pitch alongside hallucinogen-like discriminative effects. Its active metabolite 4-HO-DiPT has attracted interest as a comparatively short-acting psychedelic, and engineered prodrug forms such as RE104 have been advanced in preclinical antidepressant research. Detailed human data on 4-AcO-DiPT itself remain limited.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
agonist
agonist (via active metabolite)
agonist
agonist
agonist
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.